Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.

The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...

Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.

Cells face constant threats from inside and out. Thus, they’ve evolved sophisticated stress response pathways such as the unfolded protein response (UPR), ...

Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single genetic defect, the platform is intended to work across many underlying ...

DUBLIN--(BUSINESS WIRE)--The "Molecular Switches As Therapeutic Targets, Drug Development, Drug Delivery Mechanism & Application By Indications Insight 2025" report has been added to ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

London biotech startup Ternary Therapeutics has raised £3.6m to scale its AI-powered platform designed to engineer molecular ...